Platinum-based therapy is the mainstay for management of high-risk neuroblastoma. Prevalence of platinum-related ototoxicity has ranged from 13% to 95% in previous reports; variability is attributable to small samples and disparate grading scales. There is no consensus regarding optimal ototoxicity grading. Furthermore, prevalence and predictors of hearing loss in a large uniformly treated high-risk neuroblastoma population are unknown. We address these gaps in our study.
INTRODUCTION
Neuroblastoma, an embryonal tumor of the autonomic nervous system, is the second most common pediatric solid tumor.
1 Patients with high-risk features require dose-intensive therapy, often with cisplatin and myeloablative doses of carboplatin to maximize likelihood of survival, 2-7 increasing the risk for ototoxicity. [8] [9] [10] Platinum-related sensorineural hearing loss is generally irreversible and bilateral, and it manifests initially in the high frequencies, progressing to the speech frequencies with increasing cumulative exposure. 11, 12 The impact of hearing loss in patients with neuroblastoma is particularly significant because nearly 90% are age Ͻ 5 years at exposure to the ototoxic agents, 13 and given the short latency between exposure and ototoxicity, hearing loss occurs while language is developing. The high-frequency speech phonemes are critical to speech intelligibility 14 ; thus, even mild hearing loss in the high-frequency ranges (Ͼ 2,000 Hz) can adversely affect language development and has been associated with increased academic, social, and emotional difficulties in young children.
aminoglycosides, loop diuretics). 12, 18, 20, 21, 23, 25, 28, [30] [31] [32] Variability in ototoxicity grading criteria affect reported prevalence and severity of hearing loss and may underestimate the significance of hearing loss in children who are in the process of developing language. 25, 33 The Common Terminology Criteria for Adverse Events, version 3 (CTCAEv3; as well as prior versions), 34 and Brock criteria 20 have been used most frequently in these trials 18, 20, 24, 25, 31, [35] [36] [37] ; more recently, the American Speech-Language-Hearing Association (ASHA) 38 and Chang 39 scales have also been used to evaluate hearing loss in children with cancer, 25, 39 and evaluations based on the CTCAEv4 40 and International Society of Pediatric Oncology (SIOP-Boston) 33 scales are under way. Concerns have been raised regarding the poor correlation among these ototoxicity grading criteria and the lack of consensus regarding an optimal pediatric ototoxicity scale, 41 with the consequent lack of comparability of ototoxicity outcomes among clinical trials. 25, 33, 41, 42 In this study, we evaluated audiologic data collected in a large, uniformly treated cohort of patients with neuroblastoma who received platinum-based therapy. We aimed to: one, determine the prevalence and severity of hearing loss using four standard grading scales (ASHA, 38 Brock, 20 CTCAEv3, 34 and Chang 39 ); two, examine clinical and demographic determinants of ototoxicity; and three, evaluate concordance among the scales.
PATIENTS AND METHODS

Study Participants
Participants were enrolled between February 9, 2001, and February 24, 2006 , onto the COG (Children's Oncology Group) A3973 trial, 43 a clinical trial for patients age Յ 30 years with newly diagnosed high-risk neuroblastoma. Induction therapy included high-dose cisplatin (200 mg/m 2 ϫ 2), followed by consolidation with myeloablative carboplatin (1,700 mg/m 2 ; Appendix Table  A1 , online only). Institutions enrolled patients after obtaining approval from their local institutional review boards and securing written informed consent/ assent from patients and/or their legal representatives. Patients with postplatinum audiologic data evaluable by at least one of the four ototoxicity grading scales (Fig 1; Appendix Table A2 , online only) were included in this analysis. Institutions that contributed audiologic data are listed in the Appendix (online only).
Audiologic Assessments
Audiology reports, obtained for toxicity monitoring (conducted before first platinum exposure, after cumulative cisplatin exposure of 200 and 400 mg/m 2 , and after myeloablative doses of carboplatin for transplantation) were submitted by the treating institutions to the COG Statistics and Data Center (audiologic evaluation methods summarized in Appendix Table A3 , online only). Air-and bone-conduction thresholds (tone-burst thresholds for auditory brainstem response) for each tested frequency and details of testing (eg, type of testing performed, masking, tympanometry, use of hearing aids or assistive devices) were obtained from the audiology reports. A standardized process for audiology report interpretation was developed by the investigators (Appendix Table A3 ). Audiology reports were graded independently by two investigators (W.L., K.K.) according to each of the four grading scales. A grade was assigned to each ear with evaluable thresholds or to the soundfield; in cases where disagreement in grading between investigators existed, a consensus grading determination was made.
For each patient, the most recent postplatinum audiologic assessment that was evaluable by at least one of the four grading scales and paired with an evaluable preplatinum test (when available, to allow for grading by scales requiring preplatinum studies) was selected for inclusion in the analysis. Reports were deemed inevaluable in the presence of evident or suspected middleear pathology, insufficient range of evaluable thresholds across frequencies to allow for definitive grading, lack of tone-burst thresholds for auditory brainstem response testing (ie, clicks only), or testing completed outside acceptable date parameters (Appendix Table A4 , online only).
Main Outcome Measures
Patients were categorized by total planned per-protocol platinum dose exposure before the index audiologic assessment: exposure one (Յ cisplatin 400 mg/m 2 ) or exposure two (cisplatin 400 mg/m 2 plus carboplatin 1,700 mg/m 2 ; Fig 2) . Evaluable postplatinum audiologic assessments were categorized as follows: presence of hearing loss (yes v no) according to each of the four Evaluable patients (80.6% of patients with audiologic reports; 68.1% of all patients enrolled onto COG A3973) (n = 333)
Patients excluded (n = 76) Too ill to complete testing (n = 8) Refused testing (n = 2) Deceased before testing time point (n = 24) No audiologic data submitted (n = 42)
Reports excluded (n = 80) Not evaluable by any (n = 54) ototoxicity grading scale Testing performed outside of (n = 26) specified date parameters grading scales and severity (grade) of hearing loss according to three of the four scales (ASHA does not grade severity). Evaluable preplatinum assessments were required for evaluation per ASHA (all assessments) and CTCAEv3 (if rated Ͻ grade 3) criteria, but not for Brock or Chang. When hearing aid recommendation/use was missing from the report (required for assignment of CTCAEv3 grade Ն 3), a recommendation was assigned using pre-established criteria (Appendix Table A3 , online only); these patients were designated as requiring hearing aids. Severity grading was assigned based on the better ear. Criteria for classification of hearing loss are summarized in Table 1 .
Statistical Analyses
Inter-rater reliability was assessed using Cohen's kappa statistic.
44
The prevalence of hearing loss for each scale was calculated and compared pairwise using the generalized linear mixed-effects model. 45, 46 For patients with any hearing loss, distribution by severity of hearing loss (mild, moderate, or severe) was tabulated. Pairwise concordance among scales was evaluated using McNemar's test. 47 Between-group means were compared using the t test, and medians were compared using the Kruskal-Wallis test. 47 Unconditional multivariable logistic regression 48 was conducted to determine the risk factors of hearing loss, considering age at diagnosis, sex, race/ethnicity, cumulative platinum exposure (exposure one, cisplatin Յ 400 mg/m 2 ; exposure two, cisplatin 400 mg/m 2 plus carboplatin 1,700 mg/m 2 ), time interval between platinum and testing, preconsolidation glomerular filtration rate (marker for impaired platinum clearance 49 ), chemotherapy dose reduction during induction, and hospitalization for infection during induction (surrogate for exposure to ototoxic agents such as nonanthracycline aminoglycoside antibiotics 30, 50 ) associated with hearing loss defined by each scale. The criterion for selection of explanatory variables was .05 for entry and .10 for removal. All analyses were performed using SAS software (version 9.2; SAS Institute, Cary, NC).
RESULTS
Participant Characteristics
Of the 489 patients enrolled onto COG A3973, 333 (68.1%) were evaluable; postplatinum audiologic reports were not submitted for 76 patients; 54 were excluded because the data were not evaluable by any of the four grading scales, and 26 were excluded because testing was performed outside of the specified date parameters (Fig 1) . Of the 333 evaluable patients, 56% were male, and the median age at diagnosis was 3.3 years (range, 0.3 to 29.1 years); the most recent evaluable postplatinum audiologic testing occurred after exposure one for 66 patients (19.8%; cumulative cisplatin dose, 200 mg/m 2 for six patients and 400 mg/m 2 for 60 patients) and after exposure two for 267 patients (80.2%; cumulative cisplatin 400 mg/m 2 plus carboplatin 1,700 mg/ m 2 ; Table 2; Appendix Table A5 , online only). There were fewer male patients in the exposure-one group (P ϭ .03), and as expected, age at testing was older (5.2 v 3.7 years; P Ͻ .001) and time interval between platinum exposure and testing was longer (273 v 34 days; P Ͻ .001) in the exposure-two group. All other characteristics were comparable. For patients with available clinical data (Table 2), 82.5% required hospitalization for infection during induction, 12% required a platinum dose reduction of Ն 25%, and 19% had compromised renal function (glomerular filtration rate Ͻ 100 mL/min/1.73 m 2 ) at the end of induction.
Quality of Audiologic Assessments
Significantly fewer auditory tests were evaluable by ASHA than by any other scale (ASHA, 42.9%; CTCAEv3, 70.2%; Chang, 73.8%; Brock, 74.3%; P Ͻ .001).
Inter-Rater Reliability
A total of 1,989 ratings were independently completed by two investigators (W.L., K.K.); these included ratings of individual ears and/or soundfields according to the four scales (ASHA, 329; Brock, 570; Chang, 563; CTCAEv3, 527 ratings). Inter-rater reliability was Ն 0.95 for all scales; discrepant ratings between investigators totaled 19 (0.96%) of 1,989.
Prevalence of Hearing Loss
Prevalence of any hearing loss (Brock, CTCAEv3, and Chang, grades 1 to 4; ASHA, grades A to C) was comparable across the four grading scales (P Ͼ .05; Fig 3A) , ranging from 64% to 71% for the exposure-one group to 86% to 90% for the exposure-two group. Prevalence of severe hearing loss differed by scale ( Figs 3B and 3C ). Among exposure-one patients, prevalence of severe hearing loss was 8% per Brock, 32% per Chang, and 47% per CTCAEv3 (Brock v CTCAEv3 and Chang, P Ͻ .01; CTCAEv3 v Chang, P ϭ .16); comparable prevalences for the exposure-two cohort were 30%, 59%, and 71%, respectively (all pairwise comparisons, P Ͻ .01). Prevalence of patients requiring hearing aids was 28.8% at exposure one and 58.4% at exposure two (P Ͻ .001; Fig 3D) .
Risk Factors for Severe Hearing Loss
Multivariable analysis revealed that the odds of developing severe hearing loss in exposure-two patients ranged from odds ratios (ORs) of 3.2 per Brock (95% CI, 1.1 to 9.8; P ϭ .038) to 3.8 per CTCAEv3 (95% CI, 1.7 to 8.6; P ϭ .002) compared with exposure-one patients. Additionally, ORs of developing severe hearing loss in patients hospitalized at least once for infection during induction ranged from 1.8 per CTCAEv3 (95% CI, 0.86 to 3.7, P ϭ .124) to 5.1 per Brock (95% CI, 1.7 to 14.9; P ϭ .004) compared with those never hospitalized during induction for infection (Fig 4) .
Exposure-two patients were 3.7ϫ more likely to require a hearing aid (95% CI, 1.8 to 7.9; P ϭ .001) compared with exposure-one patients. Furthermore, patients with a history of hospitalization for infection were 2.3ϫ more likely to require a hearing aid (95% CI, 1.2 to 4.4; P ϭ .01).
Concordance Among Grading Scales
There was high concordance among the scales in detecting normal versus impaired hearing (concordant pairs: ASHA v Brock, 
DISCUSSION
In this large study using a homogeneously treated cohort of children with high-risk neuroblastoma, we found that 67% of patients had severe hearing loss (per CTCAEv3). Consistent with previous studies, 37,51 the risk for severe hearing loss was increased Ͼ three-fold by all scales after consolidation with myeloablative carboplatin, and there was up to five-fold increased risk for severe hearing loss (by Brock scale) in those hospitalized for infection during induction, a surrogate for additional ototoxic exposures (eg, nonanthracycline aminoglycoside antibiotics). Finally, this study quantified the discordance among grading scales in identifying severe hearing loss.
Dose-intensive cisplatin induction followed by myeloablative carboplatin-based consolidation are among the most efficacious agents for management of high-risk neuroblastoma 1, 3, 4, [52] [53] [54] [55] [56] ; thus, use of these agents continues despite their known ototoxic properties. In addition, these patients often experience complications necessitating exposure to additional ototoxic agents, including nonanthracycline aminoglycoside antibiotics. 30, 37, 50, 57 Mild to moderate high-frequency hearing loss has significant implications for young children because of the high-frequency fricative sounds (such as th, k, and s) required for speech discrimination 14 and identification of verb tense and pleural forms, 58 and it has been associated with academic difficulties. [15] [16] [17] In this study, Ͼ 80% of patients had at least mild hearing loss, regardless of grading scale used, with a large majority (from 61% per Brock to 81% per CTCAEv3) experiencing moderate or severe hearing loss. The functional implications of this hearing loss are substantial, with Ͼ 50% of the cohort requiring a hearing aid. Although hearing aid technology continues to improve, no hearing aid is able to restore normal hearing 14, 59 ; children with these devices require close monitoring, and most will need intensive speech/language services and specialized educational accommodations to maximize their educational potential. 25, 60 Hearing loss has significant educational and psychosocial consequences. Using data from a survey completed by parents of neuroblastoma survivors, patients with hearing loss were 2ϫ more likely to have academic problems requiring special educational services than those with intact hearing. Hearing loss was also associated with lower patient-reported school and psychosocial functioning.
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Our study found no significant differences in discriminating normal from impaired hearing (range, 99.3% to 100% concordant pairs) across grading scales. However, significant discordance was identified among the scales in identifying severe hearing loss, with Ͼ 50% discordance in assignment of severe ratings between the two most commonly used scales: CTCAEv3 and Brock. For children who received cisplatin and myeloablative carboplatin, hearing loss was rated as severe in only 30% by the Brock scale, but it was rated as severe in 59% by Chang and 71% by CTCAEv3. A similar pattern was observed for patients who received cisplatin only, with 8% receiving a rating of severe by Brock, 32% by Chang, and 47% by CTCAEv3.
The difference in severity rating between the Brock and CTCAEv3 scales is in large part a result of the reliance of the latter scale on functional outcome in defining severe hearing loss (ie, patients requiring a hearing aid are by definition assigned severe [grade 3] rating according to CTCAEv3 34 ). The Chang scale 39 is also structured to align severity ratings with functional outcomes through its rating schema, which includes evaluations of key interval frequencies (3,000 and 6,000 Hz) and thresholds Ͻ 40 dB that are typically used by audiologists in making clinical determinations regarding the need for hearing aids. Of note, the prevalence of hearing aids at both exposure one (28.8%) and exposure two (58.4%) closely approximated the prevalence of Chang severe ratings at those time points (32% and 59%, respectively).
The Brock scale 20 was the first ototoxicity scale specifically developed to assess platinum-related hearing loss, and its design was based on audiograms from 41 children with high-frequency hearing loss that sloped an average of 45 dB per octave over the impaired frequencies. Given these large decrements per octave, and assuming that hearing would be normal or only minimally impaired at the octave below, 40 dB was selected as the cutoff for significant loss at each frequency.
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The Chang scale was built on the design employed by Brock to assess the typical pattern of hearing loss seen in platinum-based regimens, but it included modifications that addressed functional deficits caused by losses Ͻ 40 dB and at interval frequencies not assessed by Brock, with the goal of aligning objective severity grading with audiologists' clinical recommendations for amplification. 39 The importance of the inclusion of modest (Ͻ 40 dB) decrements and key interval frequencies in assessing the functional implications of hearing loss (particularly with regard to need for amplification) is underscored by our finding that only 49% of children requiring a hearing aid were rated as having severe hearing loss according to the Brock scale, whereas 91% and 100% of these children received a severe rating according to the Chang and CTCAEv3 scales, respectively. Thus, the commonly used Brock scale significantly underestimated functionally severe hearing loss in this cohort.
Quantification of clinically meaningful hearing loss using standardized grading scales is of critical importance in assessing the relative toxicity of ototoxic agents used in oncology trials. In this study, we used all available data obtained during clinical auditory assessments of children participating in the COG A3973 trial to compare four commonly used ototoxicity grading scales. Our finding that postplatinum test results were inevaluable by ASHA in Ͼ 50% and by CTCAEv3 in 30% of the patients, in large part because of incomplete or inevaluable preplatinum data, is indicative that a requirement for preplatinum testing could limit the clinical applicability of a grading scale, particularly in young seriously ill children presenting with high-risk disease. Furthermore, ignoring pre-existing hearing loss and reporting grades purely as a change from preplatinum hearing status may obscure the true clinical impact of the hearing loss. 62 Although the Chang and Brock scales do not require preplatinum testing, and the proportion of patients inevaluable by these scales was lower than that by the ASHA and CTCAEv3 scales, audiologic data were inevaluable by these scales in Ͼ 25% of children, underscoring the critical need for a grading scale that maximizes understanding of a child's auditory status using an efficiently obtained minimal data set.
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The study needs to be considered in the context of its limitations. Audiologic reports submitted by 90 institutions introduced some variability in quality and also affected completeness of data submitted (68% evaluable patients). However, other than slightly older age at diagnosis (3.3 v 2.6 years), all other characteristics were comparable between the two groups. The assessors were aware of the timing of audiograms with respect to platinum exposure, but they were unaware of transplantation status or total platinum dose when they assigned scores. The use of a cross-sectional study design precluded the examination of the trajectory of decline in auditory function over time; this aspect of the study will be addressed in the future. Finally, details regarding other ototoxic agents and irradiation were not available. We used hospitalization for infection as a surrogate for exposure to additional ototoxic agents during induction, but there was no surrogate measure available after consolidation. We expect that only a small minority of patients would have received radiation therapy involving the ear, given the typical presentation of neuroblastoma in the abdomen.
In conclusion, severe hearing loss is prevalent in children with high-risk neuroblastoma treated with platinum-based chemotherapy. Vulnerability is increased with carboplatin conditioning and hospitalization for infection. There is significant discordance among audiologic grading scales in categorizing severe platinum-related hearing loss in children; the Brock scale underestimates severe hearing loss and should be used with caution in this setting. Results from this study could inform selection of grading scales for use in future studies. Data from the current study are being used to evaluate CTCAEv4 40 and the newly proposed SIOP-Boston grading scale 33 -scales that are attempting to overcome the limitations of currently available scales. 33, 41 Platinum remains one of the mainstays of induction therapy for high-risk neuroblastoma; thus, auditory monitoring, avoidance of additional ototoxic agents, and early aural rehabilitation will remain essential in optimizing long-term audiologic outcomes for these patients.
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Only for patients refusing or ineligible for myeloablative consolidation therapy; three cycles at 3-to 4-week intervals. †All patients after consolidation or maintenance; six cycles of 2 weeks on and 2 weeks off. ; if tympanogram or immittance data are not included, but audiologist rating is present, use rating (eg, type A, normal); if no tympanogram report is submitted, assume normal result (ie, audiologists typically report pertinent positives) Soundfield testing: if 25 dB is considered abnormal per the scale, record as such (ie, even though 25 dB may be considered clinically normal in the soundfield, there are no accommodations in the grading scales for this) ABR testing: normal threshold values: Յ 40 dB nHL at 500 Hz; Յ 20 dB nHL at 1,000, 2,000, 3,000, and 4,000 Hz; Յ 35 dB nHL at 6,000 Hz; Յ 40 dB nHL at 8,000 Hz (according to the correction values provided by testing audiologists); if ABR marked as Ͻ a threshold, record at that threshold (eg, Ͻ 20 dB ϭ 20 dB) ASHA If both air-and bone-conduction thresholds are present, preferentially use air-conduction thresholds Must have preplatinum data for each frequency to which ASHA criteria is applied (ie, do not assume normal preplatinum result) Brock
If both air-and bone-conduction thresholds are present, preferentially use air-conduction thresholds Must have thresholds for at least two frequencies; at least one of the frequencies must be in the 2,000-8,000 Hz range For grades 2-4: thresholds must be Ն 40 dB at all indicated frequencies for that grade; if threshold is Ն 40 dB at a given frequency, and data are missing for higher frequencies, assume that thresholds for the higher frequencies are also Ն 40 dB; if the highest frequency tested has a threshold Ͻ 40 dB, assume that all frequencies above the highest frequency tested also have thresholds Ͻ 40 dB Chang If both air-and bone-conduction thresholds are present, preferentially use bone-conduction thresholds (ie, bone-conduction thresholds are preferred data for interpretation of Chang scale; for all other scales, bone conduction is used only to determine presence of airbone gap) Assignment of grade 0 requires normal thresholds at 1,000, 2,000, and 4,000 Hz; if any of these thresholds are missing, mark as not evaluable CTCAEv3
If both air-and bone-conduction thresholds are present, preferentially use air-conduction thresholds If the threshold for a frequency is missing preplatinum, the frequency is considered not evaluable on the postplatinum audiogram unless postplatinum threshold for the frequency is normal (Յ 20 dB) Grade 2: if the average of two contiguous frequencies is Ͼ 25 dB (even if one is normal), the severity grade ϭ 2 For grade 3 (hearing loss sufficient to indicate therapeutic intervention, including hearing aids ͓eg, Ն 20 dB bilateral HL in speech frequencies, Ն 30 dB unilateral HL, and requiring additional speech-language services͔): -Speech frequencies are defined as 500-4,000 Hz -Ն 20 dB bilateral HL applies to speech frequencies 500-4,000 Hz -Ն 30 dB unilateral HL applies to speech frequencies 500-4,000 Hz -Requiring additional speech-language services is defined as FM trainer, special class/resource teacher, or equivalent intervention, but does not include basic services such as preferential seating or communication strategies In the absence of any obvious indicator of hearing aid/assistive device use (eg, explicit audiologist notation or aided audiogram), determination regarding whether hearing aids/assistive devices are indicated/in use is based on review of all available audiology notes and is made collaboratively by two investigators based on the overall prescribing pattern determined for cohort; if no data are available, and the indicator is not obvious based on the audiologic report, mark as unknown Indications for cochlear implant (CTCAEv3 grade 4): thresholds Ն 80 dB at frequencies between 500 and 4,000 Hz (not correctable with hearing aid)
